Episode 58– Dan Kemp (CEO) & Steven Katz- (CMO) of Shinobi Therpaeutics

Welcome back to another episode of The Bio Hub, we were delighted to be joined by two leaders from Shinobi Therapeutics, a company pushing the boundaries of off-the-shelf cell therapy through an innovative stealth cell platform that aims to overcome immune rejection and unlock the full potential of allogeneic CAR-T and CAR-NK therapies."With us is Dr. Dan Kemp, CEO of Shinobi Therapeutics. Dan brings over two decades of experience at the intersection of science and business in the cell and gene therapy space. He earned his PhD in molecular pharmacology from the University of Kent, completed postdoctoral work at Massachusetts General Hospital, and held an HHMI fellowship at Harvard Medical School. His industry leadership spans major roles at Takeda, where he helped shape the company’s cell therapy strategy, and as CEO of Wugen, where he advanced off-the-shelf NK and CAR-T therapies through key stages of developmentAlso with us is Dr Steven Katz, a medical oncologist and physician-scientist with a long-standing focus on immuno-oncology and cellular therapies. Before joining Shinobi, Dr. Katz held leadership roles guiding early clinical development and translational strategy at TriSalus Life Sciences. His work has consistently centered on designing and executing clinical trials that bring advanced therapies—especially cell-based treatments—closer to patients. Now at Shinobi, he plays a critical role in shaping the company’s clinical vision, steering development programs for immune-evasive, off-the-shelf cell therapies, and leading efforts to move first-in-class products into the clinic.